DREXEL UNIVERSITY
Testing a new therapy for SPG4 Hereditary Spastic Paraplegia
Testing a new therapy for SPG4 Hereditary Spastic Paraplegia is a funding opportunity from DREXEL UNIVERSITY, up to 228688, closing March 31, 2028.
Mar 31, 2028
(609d left)Overview
SUMMARY/ABSTRACT Hereditary Spastic Paraplegia 4 (SPG4-HSP) is an underdiagnosed neurodegenerative disorder characterized by progressive weakness and spasticity in both legs that escalate into wheelchair dependence. Symptoms result mainly from dying-back degeneration of corticospinal tracts. The disease is caused by…